|
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
| Estimated average burden hours per response... | 0.5 |
|
|
(Print or Type Responses)
|
1. Name and Address of Reporting Person *
|
| SHERMAN STEVEN |
|
2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [EKSO]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
__X__ Director
|
_____ 10% Owner
|
|
__X__ Officer (give title below)
|
_____ Other (specify below)
|
|
CEO & Chairman
|
|
|
C/O EKSO BIONICS HOLDINGS, INC., 101 GLACIER POINT, SUITE A |
3. Date of Earliest Transaction (Month/Day/Year)
09/21/2022 |
|
SAN RAFAEL, CA 94901 |
4. If Amendment, Date Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|
1.Title of Security
(Instr. 3)
|
2. Transaction Date (Month/Day/Year)
|
2A. Deemed Execution Date, if any (Month/Day/Year)
|
3. Transaction Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
|
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 09/21/2022 |
| M |
| 15,599 | A |
$
0
| 694,594 | D |
|
| Common Stock | 09/22/2022 |
| S |
| 6,043 (1) | D |
$1.7463 (2) | 688,551 | D |
|
|
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (Month/Day/Year)
|
3A. Deemed Execution Date, if any (Month/Day/Year)
|
4. Transaction Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
|
6. Date Exercisable and Expiration Date
(Month/Day/Year)
|
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
|
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
| Restricted Stock Units | (3) | 09/21/2022 |
| M |
|
| 15,599 |
(4) |
(4) | Common Stock | 15,599.00 |
$
0
| 62,398 | D |
|
Reporting Owners
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
SHERMAN STEVEN
C/O EKSO BIONICS HOLDINGS, INC.
101 GLACIER POINT, SUITE A
SAN RAFAEL, CA 94901 |
X
|
|
CEO & Chairman |
|
Signatures
| /s/ Jerome Wong, as Attorney-in-Fact | |
09/26/2022 |
| **Signature of Reporting Person | Date |
Explanation of Responses:
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | Represents shares sold by the Reporting Person on September 22, 2022 to cover tax withholding obligations incurred upon the vesting and settlement of the eighth installment of a restricted stock award originally reported by the Reporting Person in Form 4 filed with the Commission on March 10, 2022. |
| (2) | The sale price represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $1.70 to $1.80, inclusive. The Company can provide the full information regarding the number of shares sold at each separate price upon further request. |
| (3) | The restricted stock units ("RSUs") were granted on March 8, 2022 in accordance with the terms of an Executive Employment Agreement entered into between the Reporting Person and the Company on January 21, 2022 (the "Effective Date"). |
| (4) | The RSUs vest in twelve equal installments on the first twelve monthly anniversaries of the Effective Date, starting February 21, 2022, such that the RSUs will be fully vested as of January 21, 2023. The eighth installment of RSUs vested on September 22, 2022 and were delivered to the Reporting Person upon settlement. |
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
|
